Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aguiar-Bujanda, D.
Right arrow Articles by Bohn-Sarmiento, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aguiar-Bujanda, D.
Right arrow Articles by Bohn-Sarmiento, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2004; 97: 55-56
© Association of Physicians 2004; all rights reserved.

Correspondence

Sweet's syndrome associated with norfloxacin in a prostate cancer patient

The first 10% of the full text of this article appears below.

Sir,

Acute febrile neutrophilic dermatosis, also termed Sweet's syndrome (SS), is an uncommon disease first described by Robert Sweet in 1964.1 It is a hypersensitivity reaction in response to systemic factors, which may include malignant disease, infection, or drug exposure. Patients with malignancy often take several medications, and if SS develops, it can be difficult to tell whether it is drug-related or a paraneoplastic syndrome.

Norfloxacin is an antibiotic from the family of . . . [Full Text of this Article]

D. Aguiar-Bujanda, J. Aguiar-Morales and U. Bohn-Sarmiento

Servicio de Oncología Médica Hospital de Gran Canaria Dr Negrin Las Palmas Spain e-mail: dagubuj@gobiernodecanarias.org


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?